Please assess the completion status of the following clinical trial:

Trial Title: Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants must be at least 18 years of age, inclusive, at the time of signing the informed consent form.~* Confirmed SARS-CoV-2 polymerase chain reaction (PCR) positive patient within 5 days of enrollment, as shown by medical history and reported PCR test result.~* Reports having one or more symptoms consistent with SARS-CoV-2, as defined in Master Protocol Appendix 3 Table 4.~* COVID-19 diagnosis must be WHO grade ≤3.~* Contraceptive use by men or women should be consistent with Appendix 4 of the Master protocol (LDOS-21-001).~* Reliable access to the Internet via a browser installed on personal device or computer.~* Capable of understanding and providing signed informed consent.~Exclusion Criteria:~* Pregnancy or breastfeeding~* Ongoing antiviral or antiretroviral treatment~* Known history of HIV~* Ongoing anti-inflammatory treatment that cannot be temporarily discontinued during the study. This includes nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids - including Dexamethasone (dexamethasone administration restricted to recommended standard of care use per NIH COVID-19 Guidelines)~  1. drugs dependent on gastric pH for absorption, e.g., dasatinib, delavirdine, mesylate, cefditoren, and fosamprenavir;~ 2. tizanidine (CYP1A2) substrate;~ 3. drugs that interfere with hemostasis (e.g., warfarin, aspirin, selective serotonin reuptake inhibitors \[SSRIs\]/serotonin norepinephrine reuptake inhibitors (SNRIs\]);~ 4. angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), or beta-blockers;~ 5. diuretics;~ 6. digoxin~* Ongoing treatment that cannot be temporarily discontinued during the study, with: antimalarials, antiarrhythmics, tricyclic antidepressants, natalizumab, quinolones, macrolides, agalsidase alfa and beta~* Ongoing famotidine or celecoxib or other COVID-19 clinical investigational treatment(s) within the past 30 days, or current participation in another investigational clinical trial~* History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs~* History of immunosuppression~* Rejection of participation by Principal Investigator or Sponsor~* Any contraindication for famotidine or celecoxib treatment:~  1. Famotidine or celecoxib hypersensitivity~ 2. Retinopathy, visual field or visual acuity disturbances~ 3. History of cardiovascular disease, such as congestive heart failure, QT prolongation, myocardial infarction, bradycardia (\<50 bpm), ventricular tachycardia, other arrhythmias~ 4. Myasthenia gravis~ 5. Psoriasis or porphyria~ 6. History of renal failure/dialysis or a glomerular clearance \<60 mL/min~ 7. History of severe hypoglycemia~ 8. Moderate or severe hepatic impairment, e.g., Child-Pugh Class B or C~ 9. Known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history or experience with other CYP2C9 substrates, such as warfarin and phenytoin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Study Product) (Type: EXPERIMENTAL): Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.
- Group 2 (Reference Therapy) (Type: PLACEBO_COMPARATOR): Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, participants will continue to receive matching famotidine placebo, QID, for an additional 9 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).